Trevi Therapeutics has named Dr. David Clark as its new chief medical officer.
Clark has more than 25 years of global clinical development experience in big pharma and biotech. He most recently served as CMO at Allena Pharmaceuticals, and he has had similar roles at companies such as Aldeyra Therapeutics, Wilson Therapeutics and NormOxys.
The company is developing the investigational therapy Haduvio to treat chronic cough in adults with idiopathic pulmonary fibrosis and other chronic cough indications, and for the treatment of the skin condition prurigo nodularis.
Jennifer Good, president and CEO of Trevi, said she is pleased to welcome Clark to the leadership team. “We believe his strong track record as a biotech CMO and successful delivery of Phase 3 programs will enable David to play a key role as we progress,” Good said.